These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 32947651)

  • 1. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of
    Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
    J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
    Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E
    Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV
    Fan Y; Zhang Y; Yang Z; Ying Z; Zhou N; Liu C; Song Y; Zhu J; Wang X
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28535082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET-derived tumor metrics predict DLBCL response and progression-free survival.
    Islam P; Goldstein J; Flowers CR
    Leuk Lymphoma; 2019 Aug; 60(8):1965-1971. PubMed ID: 30714446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.
    Ceriani L; Gritti G; Cascione L; Pirosa MC; Polino A; Ruberto T; Stathis A; Bruno A; Moccia AA; Giovanella L; Hayoz S; Schär S; Dirnhofer S; Rambaldi A; Martinelli G; Mamot C; Zucca E
    Blood Adv; 2020 Mar; 4(6):1082-1092. PubMed ID: 32196557
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
    Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognosis value of early and interim ¹⁸F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma].
    Zhang Y; Fan Y; Yang Z; Ying Z; Song Y; Zhu J; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 2015 Oct; 36(10):824-9. PubMed ID: 26477759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
    Kim J; Song YS; Lee JS; Lee WW; Kim SE
    Leuk Lymphoma; 2018 Feb; 59(2):340-347. PubMed ID: 28629257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
    Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
    Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of
    Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
    Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
    Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
    J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.